Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xian-Janssen Promotes Its Paliperidone By Means Of Academic Promotion

This article was originally published in PharmAsia News

Executive Summary

The Chinese Society of Psychiatry, under the Chinese Medical Association, and Xian-Janssen have jointly started a personal and social performance scale training (PSP) course in Guangzhou. The nationwide training program aims to apply scientific psychiatric diagnosis and treatment concepts to clinical practice. Industry observers believe that besides popularizing these concepts, Xian-Janssen is more interested in promoting its schizophrenia drugs. In February this year, the firm introduced in China its extended-release paliperidone tablets, the first FDA-approved anti-psychotic drug that can significantly improve a patient's personal and social functioning, as proven by PSP. Analysts note that pharmaceutical MNCs' advantages in the psychiatry field can be ascribed to their developed academic promotion system. (Click here for more - Chinese Language)

You may also be interested in...



Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.

UsernamePublicRestriction

Register

SC072389

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel